News

3 November 2008

 

Replisaurus secures €7m to commercialize metallization technology

Replisaurus Technologies Inc of Kista, near Stockholm, Sweden says that Noble Venture Finance has committed venture financing of €7m that puts it in a strong position to start commercializing its new, clean metallization technology for high-volume chip packaging.

The financing is one of the largest commitments that Noble Venture Finance has made to a technology company.

“Given the difficult economic climate, it shows that companies with strong, forward-looking technology can still attract investments,” says CEO James Quinn. Last month Replisaurus won a EuroAsia IC Industry Cleantech award for its ElectroChemical Pattern Replication (ECPR) technology. The firm says that its electrochemical replication principle combines the precision and resolution of advanced lithography with the ease and efficiency of electrochemical deposition into a single integrated process, eliminating many steps from the traditional packaging process, as well as solvents, developers and strippers. “Our economical, fab-friendly, environmentally clean technology will help other companies reduce their carbon footprint,” Quinn adds.

Along with its environmental benefits, Replisaurus claims that ECPR reduces metallization complexity, and boosts production speed, addressing both technical and economic issues. Initial target markets include key growth sectors such as integrated passives, copper pillars and 3D integration.

“Replisaurus has a strong enabling technology focused on a large and growing market and it has impeccable cleantech credentials,” says Noble Venture Finance director Andrew Webster. “It has attracted investment from the top tier of Europe’s venture capital community, and the first-class management team has real passion that has attracted key industry specialists to join the company.”

Early in October, Replisaurus announced that Mike Thompson, former deputy CTO of STMicroelectronics, had joined the firm as chief operating officer. Thompson is in charge of the integration of ECPR technology into a high-volume manufacturing solution, in preparation for commercial sales.

See related item:

Replisaurus acquires S.E.T. to expand operations, production capacity and product portfolio

Visit: www.replisaurus.com